Doering P L, Russell W L, McCormick W C, Klapp D L
College of Pharmacy, University of Florida, Gainesville 32610.
Drug Intell Clin Pharm. 1988 Feb;22(2):125-30. doi: 10.1177/106002808802200204.
Health maintenance organizations (HMO) are growing in number as a cost-effective way of providing health care. In some, stringent formulary management policies including programs authorizing therapeutic substitution are practiced. Under this concept a drug that has been previously determined to be therapeutically equivalent to a second drug, even though it is not chemically equivalent to the prescribed drug, is automatically dispensed without contacting the prescriber. This study was undertaken to learn the extent and conditions under which therapeutic substitution is being practiced in the HMO setting. A survey was sent to all HMO in the U.S. inquiring into the operation of the pharmacy services. Specific focus was on the operation of the formulary and the policies and procedures being followed. The main goal was to learn how many programs authorize therapeutic substitution, what drugs are allowed, and what procedures are followed once the substitution is made. Of the 481 surveys sent out, 192 (40 percent) usable responses were received. Results indicate that 30.5 percent of HMO pharmacy plans allow therapeutic substitution. These programs were most likely to be of the staff-model or the group-model and least likely to be of the independent practice association type. HMO with an inhouse pharmacy more frequently had policies allowing therapeutic substitution than those using outside pharmacy services.
作为一种具有成本效益的医疗保健提供方式,健康维护组织(HMO)的数量正在不断增加。在一些组织中,实行了严格的处方集管理政策,包括授权治疗性替代的计划。在这一概念下,一种先前已被确定在治疗上等同于另一种药物的药物,即使它在化学上与处方药不等同,也会在不联系开处方者的情况下自动配药。本研究旨在了解在HMO环境中实行治疗性替代的程度和条件。向美国所有的HMO发送了一份调查问卷,询问药房服务的运作情况。特别关注处方集的运作以及所遵循的政策和程序。主要目标是了解有多少计划授权治疗性替代、允许使用哪些药物以及进行替代后遵循哪些程序。在发出的481份调查问卷中,收到了192份(40%)可用回复。结果表明,30.5%的HMO药房计划允许治疗性替代。这些计划最有可能是员工模式或团体模式,最不可能是独立执业协会类型。拥有内部药房的HMO比使用外部药房服务的HMO更频繁地制定允许治疗性替代的政策。